Add-on fluvoxamine treatment for schizophrenia: An updated meta-analysis of randomized controlled trials

European Archives of Psychiatry and Clinical Neuroscience

Volumn 263, Issue 8, 2013, Pages 633-641

  Kishi, Taro ^a   Hirota, Tomoya ^b   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fluvoxamine; Meta analysis; Randomized controlled trial; Schizophrenia; Systematic review

Indexed keywords

BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIAZEPAM; FLUVOXAMINE; HALOPERIDOL; OLANZAPINE; PEROSPIRONE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; TRIHEXYPHENIDYL;

ADD ON THERAPY; ADJUVANT THERAPY; CONSTIPATION; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HOSPITAL PATIENT; HUMAN; HYPERSALIVATION; META ANALYSIS; MONOTHERAPY; NAUSEA; NEGATIVE SYNDROME; ORTHOSTATIC HYPOTENSION; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYMPTOM ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; FLUVOXAMINE; HUMANS; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84889604538     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-013-0406-3     Document Type: Review

References (44)

1. Albayrak Y, Ekinci O (2012) Duloxetine-associated tardive dyskinesia resolved with fluvoxamine: a case report. J Clin Psychopharmacol 32:723-724
2. Andreasen NC (1982) Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39:784-788
3. Andreasen NC (1985) Positive vs. negative schizophrenia: a critical evaluation. Schizophr Bull 11:380-389
4. Ault DT, Werling LL (1999) Phencyclidine and dizocilpine modulate dopamine release from rat nucleus accumbens via sigma receptors. Eur J Pharmacol 386:145-153
5. Bouchard P, Quirion R (1997) [3H]1,3-di(2-tolyl)guanidine and [3H](+)pentazocine binding sites in the rat brain: autoradiographic visualization of the putative sigma1 and sigma2 receptor subtypes. Neuroscience 76:467-477
6. Chaichan W (2004) Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia. Psychiatry Clin Neurosci 58:364-368
7. Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr (2003) The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol 23:668-671
8. Correll CU, Lencz T, Malhotra AK (2011) Antipsychotic drugs and obesity. Trends Mol Med 17:97-107
9. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, J Am Med Assoc 302:1765-1773
10. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
11. Furuse T, Hashimoto K (2010) Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors. Ann Gen Psychiatry 9:11
12. Furuse T, Hashimoto K (2010) Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases. Ann Gen Psychiatry 9:17
13. Gonzalez-Alvear GM, Thompson-Montgomery D, Deben SE, Werling LL (1995) Functional and binding properties of sigma receptors in rat cerebellum. J Neurochem 65:2509-2516
14. Gronier B, Debonnel G (1999) Involvement of sigma receptors in the modulation of the glutamatergic/nmda neurotransmission in the dopaminergic systems. Eur J Pharmacol 368:183-196
15. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
16. Hashimoto K, Fujita Y, Iyo M (2007) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 32:514-521
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560
18. Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmacher T (2000) Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology 149:163-169
19. Inada T, Yagi G, Miura S (2002) Extrapyramidal symptom profiles in japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res 57:227-238
20. Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K (2007) High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11c]SA4503. Biol Psychiatry 62:878-883
21. Iyo M, Shirayama Y, Watanabe H, Fujisaki M, Miyatake R, Fukami G, Shiina A, Nakazato M, Shiraishi T, Ookami T, Hashimoto K (2008) Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32:1072-1073
22. Kay SR, Opler LA, Lindenmayer JP (1989) The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry (Suppl 7):59-67
23. Kishi T, Matsuda Y, Nakamura H, Iwata N (2013) Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res 47(2):149-154. doi: 10.1016/j.jpsychires. 2012.10.011
24. Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, De Thomas C, Kafantaris V, Correll CU, Kane JM (2008) Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 63:524-529
25. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41
26. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152-163
27. Li C, Xia J, Wang J (2009) Risperidone dose for schizophrenia. Cochrane Database Syst Rev CD007474
28. Lu ML, Lane HY, Lin SK, Chen KP, Chang WH (2004) Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 65:766-771
29. Meltzer HY (2013) Update on typical and atypical antipsychotic drugs. Annu Rev Med 64:393-406
30. Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yagcioglu AE, Small JG (2008) A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 69:274-285
31. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry J Mental Sci 134:382-389
32. Narita N, Hashimoto K, Tomitaka S, Minabe Y (1996) Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 307:117-119
33. Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T, Fukami G, Nakazato M, Shirayama Y, Hashimoto K, Iyo M (2012) A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J Clin Psychopharmacol 32:593-601
34. Niitsu T, Shirayama Y, Fujisaki M, Hashimoto K, Iyo M (2010) Fluvoxamine improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 34:1345-1346
35. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799-812
36. Reznik I, Sirota P (2000) Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. J Clin Psychopharmacol 20:410-416
37. Sepehry AA, Potvin S, Elie R, Stip E (2007) Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clinical Psychiatry 68:604-610
38. Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M (2000) Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 15:257-261
39. Silver H, Nassar A (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 31:698-704
40. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19
41. Singh SP, Singh V, Kar N, Chan K (2010) Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry J Mental Sci 197:174-179
42. Weatherspoon JK, Gonzalez-Alvear GM, Frank AR, Werling LL (1996) Regulation of [3H] dopamine release from mesolimbic and mesocortical areas of guinea pig brain by sigma receptors. Schizophr Res 21:51-62
43. Yamazaki Y, Ishioka M, Matsubayashi H, Amano T, Sasa M (2002) Inhibition by sigma receptor ligand, MS-377, of N-methyl- D-aspartate-induced currents in dopamine neurons of the rat ventral tegmental area. Psychopharmacology 161:64-69
44. Zambon S, Fontana S, Kajbaf M (2010) Evaluation of cytochrome p450 inhibition assays using human liver microsomes by a cassette analysis/LC-MS/MS. Drug Metab Lett 4:120-128